1．Pugsley MK，Tabrizchi R．The vascular system．An overview of structure and function．J Pharmacol Toxicol Methods，2000，44( 2) : 333-340．

2．Sperelakis N．Chemical agent actions on ion channels and electrophysiology of the heart//Acosta D．Cardiovascular Toxicology．2nd ed．New York: Raven Press，1992．

3．Christ M，Wehling M．Cardiovascular steroid actions: swift swallows or sluggish snails? Cardiovasc Res，1998，40 ( 1) : 34-44．

4．Pulkki KJ．Cytokines and cardiomyocyte death．Ann Med，1997，29( 4) : 339-343．

5．Harpel PC．Homocysteine，atherogenesis and thrombosis．Fibrinolysis Proteolysis，1997，11 suppl 1: 77-80．

6．Klaassen CD．Casarett and Doull’s toxicology: the basic science of poisons．7th ed．New York: McGraw-Hill Companies，Inc．，2008．

7．Hodgson E．A textbook of modern toxicology．4th ed．New Jersey: John Wiley＆Sons，Inc．，2010．

8．Gad SC．Preclinical development handbook: toxicology．New Jersey: John Wiley＆Sons，Inc．，2008．

9．Stummann TC，Beilmann M，Duker G，et al．Report and recommendations of the workshop of the European Centre for the validation of alternative methods for drug-induced cardiotoxicity．Cardiovasc Toxicol，2009，9( 3) : 107-125．

10．Satomi K，Shimizu W，Takaki H，et al．Response of beat-by-beat QT variability to sympathetic stimulation in the LQT1 form of congenital long QT syndrome．Heart Rhythm，2005，2( 2) : 149-154．

11．Vargas HM，Bass AS，Breidenbach A，et al．Scientific review and recommendations on preclinical cardiovascular safety evaluation of biologics．J Pharmacol Toxicol Methods，2008，58( 2) : 72-76．

12．Van Vliet BN，Chafe LL，Antic V et al．Direct and indirect methods used to study arterial blood pressure．J Pharmacol Toxicol Methods，2000，44( 2) : 361-373．

13．Walker DB．Serum chemical biomarkers of cardiac injury for nonclinical safety testing．Toxicol Pathol，2006，34 ( 1) : 94-104．

14．Bakhtiar R．Biomarkers in drug discovery and development．J Pharmacol Toxicol Methods，2008，57( 2) : 85-91．

15．Dotsenko O，Chackathayil J，Lip GY．Cardiac biomarkers: myths，facts and future horizons．Expert Rev Mol Diagn，2007，7( 6) : 693-697．

16．Vasan RS．Biomarkers of cardiovascular disease: molecular basis and practical considerations．Circulation，2006，113( 19) : 2335-2362．

17．May A，Wang TJ．Evaluating the role of biomarkers for cardiovascular risk prediction: focus on CRP，BNP and urinary microalbumin．Expert Rev Mol Diagn，2007，7( 6) : 793-804．

18．Gerszten RE，Wang TJ．The search for new cardiovascular biomarkers．Nature，2008，451( 7181) : 949-952．

19．Carlquist JF，Muhlestein JB，Anderson JL．Lipoprotein-associated phospholipase A2: a new biomarker for cardiovascular risk assessment and potential therapeutic target．Expert Rev Mol Diagn，2007，7( 5) : 511-517．

20．Csonka C，Kupai K，Kocsis GF，et al．Measurement of myocardial infarct size in preclinical studies．J Pharmacol Toxicol Methods，2010，61( 2) : 163-170．

21．Wu AHB．Cardiac markers．New Jersey: Humana Press Inc．，1998．

22．Schroeder F，Jolly CA，Cho TH，et al．Fatty acid-binding protein isoforms: structure and function．Chem Phys Lipids，1998，92( 1) : 1-25．

23．Lescuyer P，Allard L，Hochstrasser DF，et al．Heart-fatty acid-binding protein as a marker for early detection of acute myocardial infarction and stroke．Mol Diagn，2005，9( 1) : 1-7．

24．Nakata T，Hashimoto A，Hase M，et al．Human heart-type fatty acid-binding protein as an early diagnostic and prognostic marker in acute coronary syndrome．Cardiology，2003，99( 2) : 96-104．

25．Chan CP，Sanderson JE，Glatz JF，et al．A superior early myocardial infarction marker．Human heart-type fatty acid-binding protein．Z Kardiol，2004，93( 5) : 388-397．

26．Kaczyska A，Pelsers MM，Bochowicz A，et al．Plasma heart-type fatty acid binding protein is superior to troponin and myoglobin for rapid risk stratification in acute pulmonary embolism．Clin Clim Acta，2006，371( 1-2) : 117-123．

27．Setsuta K，Seino Y，Ogawa T，et al．Use of cytosolic and myofibril marker in the detection of ongoing damage in patients with chronic heart failure．Am J Med，2002，113( 9) : 717-722．

28．Setsuta K，Seino Y，Kitahara Y，et al．Elevated levels of both cardiomyocyte membrane and myofibril damage markers predict adverse outcomes in patients with chronic heart failure．Circ J，2008，72( 4) : 569-574．

29．Ishino M，Takeishi Y，Niizeki T，et al．Risk stratification of chronic heart failure patients by multiple biomarkers．Circ J，2008，72( 11) : 1800-1805．

30．罗以勤，李芳秋，武建国．心型脂肪酸结合蛋白的测定及临床意义．临床检验杂志，2001，19( 5) : 312-313．

31．顾菊康．心血管系统//工业毒理学实验方法编写组．工业毒理学实验方法．上海:上海科学技术出版社，1979．

32．刘建文．药理试验方法学-新技术与新方法．北京:化学工业出版社，2003．

33．陈修，陈维洲，曾贵云．心血管药理学．第3版．北京:人民卫生出版社，2003．

34．王心如．毒理学基础．第4版．北京:人民卫生出版社，2004．

35．国家食品药品监督管理局药品审评中心．化学药物一般药理学研究技术指导原则．北京:国家食品药品监督管理局药品审评中心，2005．